Buy A2 Milk on infant formula expansion into Asia Buy A2 Milk on infant formula expansion into Asia Buy A2 Milk on infant formula expansion into Asia

Buy A2 Milk on infant formula expansion into Asia

Trade View
Medium Term / Buy
Picture of Peter Garnry
Peter Garnry

Head of Saxo Strats

Instrument: A2M:xasx
Price Target: AUD 15
Market Price: AUD 9.93


a2 Milk expands into Asia

The highest-ranked stock in our global equity factor model is a New Zealand company called a2 Milk. The dairy company sells A2 protein-based milk in primarily Australia, New Zealand, China, the UK, and the US. Its main products are liquid milk and infant formula and it has one of the highest return on invested capital ratios in our global universe of 1,700 stocks.

Additionally, the company has very low leverage on its balance sheet and strong price momentum.

The reversal factor is also very high as the company has underperformed global equities massively in the past month. Disappointing revenue guidance on May 16 drove the share price down by 13%. Overall, the business is still growing fast with 12-month trailing revenue up 55% compared to a year ago.

Competition is heating up for a2 Milk as the fast growing company has seen other dairy firms shift their marketing focus on A2 protein-based milk (there is still a lot of uncertainty over the health benefits of A2 milk, but we will get back to that shortly).

New Zealand's a2 Milk is growing quickly with revenue currently at NZD 728m up from NZD 155m in 2015 (full-year fiscal ends on June 30). The EBITDA margin is at healthy 30.3% and the CAPEX levels are extremely low leading to a very high ROIC and free cash flow generation. Strong business fundamentals usually come with high valuation and a2 Milk is expensive with a 12-month trailing EV/EBITDA ratio of 34.9x compared to 11.7x for global equities.

This high valuation premium is naturally a key risk. In addition, the downward volatility factor is also quite bad indicating significant downside moves on negative surprises. It is important to be aware of these things before investing in a2 Milk.

As the segment table and charts below show, the fastest growing market for a2 Milk is China/Asia but the biggest is still Australia and New Zealand (80% of total revenue). The main growth is coming from infant formula, which is linked to the trend of parents being more aware of health issues related to their kids. According to a2 Milk, A2 protein-based milk is better for the stomach so the marketing campaigns are obviously focused on these benefits towards young families.

Based on the firm's growth rate, the strategy is working and the Chinese market has the potential to become the biggest market for a2 Milk as Chinese consumers have experienced horrible accidents with domestically produced infant formula. The consequent lack of trust in domestic producers will likely become a key driver of growth in China. In addition, a2 Milk announced in April that it is moving into South Korea, thus expanding further into Asia. 


Entry: AUD 9.5 to 10.5
Stop: 200-day moving average (currently at AUD 8.56)
Target: AUD 15
Time Horizon: Medium term

We look to buy shares of New Zealand-based a2 Milk on the company's planned expansion into Asia.

Equity Radar
Source: Saxo Bank
Segment financial performance
Source: a2 Milk
a2 Milk
Source: Saxo Bank
Management And Risk Description:

There are several key risks to be aware of before investing in a2 Milk:

   • The benefits of A2 proteins may be overstated and could lead to brand damage if findings show no evidence of health effects.    • A2 Milk has avoided two lawsuits with the latest being settled in December with its competitor Lion Dairy & Drinks.
   • Increasing competition from other dairy firms expanding into A2 milk production, lower growth rates and operating margins.
   • Slowdown in Chinese expansion because the valuation hinges on massive growth in China.
   • Supply issues from A2 milk producers in New Zealand leading to production constraints and higher prices.
   • High valuation is a key risk as lower-than-expected growth could quickly lead to a sharp revaluation of the company’s shares.


A compiled overview of Trade Views provided on can be found here (


The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (
- Full disclaimer (

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15

Contact Saxo

Select region


Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

This website can be accessed worldwide however the information on the website is related to Saxo Bank A/S and is not specific to any entity of Saxo Bank Group. All clients will directly engage with Saxo Bank A/S and all client agreements will be entered into with Saxo Bank A/S and thus governed by Danish Law.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.